FDA's Breakthrough Devices Program offers priority review, sprint discussions, and more intensive FDA engagement for devices that treat or diagnose life-threatening or irreversibly debilitating conditions and meet one of four innovation criteria set by the 21st Century Cures Act. It speeds up interaction with FDA. It does not lower the evidence bar. The EU has no direct equivalent — the innovation route in Europe runs through the regular MDR pathway with different support mechanisms.

By Tibor Zechmeister and Felix Lenhard.

TL;DR

  • The Breakthrough Devices Program is authorized by Section 515B of the FD&C Act, added by the 21st Century Cures Act of 2016.
  • Eligibility requires the device to treat or diagnose a life-threatening or irreversibly debilitating condition AND meet one of four innovation criteria.
  • Benefits include priority FDA review, sprint discussions, data development plans, and senior FDA engagement.
  • The program does not lower the statutory standard of safety and effectiveness; you still need the same evidence base you would need for a regular De Novo, 510(k), or PMA.
  • EU MDR has no direct equivalent. The closest conceptual analogues are the MDCG structured dialogue mechanisms and the expert panels under Article 106, plus EIC Accelerator funding support.
  • For dual-market startups, a Breakthrough Designation is an FDA-only benefit. It does not change your EU MDR path, your CE marking timeline, or your Notified Body interactions.

Why this matters

Founders hear "breakthrough" and think of it as a golden ticket. It is not. It is a mechanism for faster and deeper conversations with FDA during pre-market development, and a signal to investors and payers that your device is innovative enough to meet a specific statutory definition. But a designation does not make your clinical trial smaller, your QMS simpler, or your evidence requirements lighter. Teams that treat it as a shortcut are setting themselves up for a painful correction later.

We have seen EU startups pursue Breakthrough Designation for exactly the right reasons — genuine unmet medical need, a credible innovation claim, a US-first commercial strategy — and reap real benefits from the sprint discussion process. We have also seen teams pursue it for the press release and get nothing useful out of it. The difference is always about whether the designation fits the regulatory strategy or whether it is bolted on for optics.

What FDA actually says

The Breakthrough Devices Program lives in Section 515B of the Federal Food, Drug, and Cosmetic Act, added by Section 3051 of the 21st Century Cures Act in 2016. FDA has published guidance implementing the program.

Eligibility criteria. A device is eligible for designation if it meets both of the following:

  1. The device provides for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions, AND
  2. The device meets at least one of the following: - It represents breakthrough technology; - No approved or cleared alternatives exist; - It offers significant advantages over existing approved or cleared alternatives, including the potential, compared to existing approved alternatives, to reduce or eliminate the need for hospitalization, improve patient quality of life, facilitate patients' ability to manage their own care, or establish long-term clinical efficiencies; - Device availability is in the best interest of patients.

Benefits of designation. Once FDA grants a designation, the manufacturer is eligible for:

  • Interactive and timely communication with FDA during device development and pre-market review.
  • Sprint discussions — short, focused discussions on specific scientific or regulatory questions with explicit timelines for FDA response.
  • Data development plans — agreed-upon plans for what data will support the pre-market submission.
  • Clinical protocol agreement mechanism for trial design.
  • Senior management engagement at FDA, including involvement of FDA leadership in key decisions.
  • Priority review of the eventual marketing submission, whether that is a De Novo, 510(k), PMA, or HDE.

What the program does not do. This part matters most. Breakthrough Designation does not:

  • Change the statutory standard of safety and effectiveness.
  • Guarantee clearance or approval of the eventual marketing submission.
  • Waive clinical trial requirements.
  • Exempt the manufacturer from QMS requirements (21 CFR 820, transitioning to 21 CFR 820 as amended for QMSR).
  • Reduce the data needed to support the submission.
  • Apply to the EU market in any way.

A worked example: a cardiac monitoring wearable

An Austrian startup develops a wearable that continuously monitors cardiac rhythms and uses an algorithm to detect a specific arrhythmia associated with sudden cardiac death. The team has CE marking under MDR as a Class IIa device in hand and is now preparing a US submission. They are considering whether to apply for Breakthrough Designation.

Eligibility check. The condition is life-threatening — sudden cardiac death meets the statutory threshold. Is the device innovative? Existing Holter monitors and implantable loop recorders exist. The team argues that their wearable form factor, continuous monitoring, and algorithmic detection together offer significant advantages over existing alternatives in terms of patient adherence and early detection. That is a defensible argument for criterion three (significant advantages). The team prepares a designation request.

FDA decision. FDA grants the designation. The team now has access to sprint discussions.

Using sprint discussions well. The team uses one sprint discussion to align with FDA on the endpoint definition for their pivotal study. They use another to confirm FDA's expectations on algorithm validation data. These are the exact questions that would otherwise take months of written Q-submissions. The designation saves them roughly four months of pre-submission back-and-forth.

What did not change. The clinical study size did not shrink. The QMS requirements did not relax. The cybersecurity documentation burden under FDA's premarket cybersecurity guidance stayed identical. The MDR work in the EU was entirely separate and unaffected. The breakthrough designation accelerated their conversation with FDA. It did not build their evidence base for them.

Commercial signal. The team uses the designation in investor conversations. It is a genuine differentiator. They do not oversell it as "FDA approved" or "fast-tracked for clearance" — both of which would be factually wrong.

The Subtract to Ship playbook

If you are an EU startup considering Breakthrough Designation, run this sequence before you spend a single euro on the application.

1. Be honest about the clinical condition. If your device does not target a life-threatening or irreversibly debilitating condition, you are not eligible. Wellness adjacencies and quality-of-life improvements in non-severe conditions do not qualify. Do not try to stretch the definition — FDA has seen every stretch and rejects most of them.

2. Pick one innovation criterion and defend it properly. Do not list all four criteria hoping one will stick. Pick the strongest and write a tight, evidence-backed argument. If your strongest criterion is "significant advantages," quantify the advantages against named competitors.

3. Decide whether the sprint discussions are actually valuable to you. The biggest practical benefit is the sprint discussion mechanism. If you do not have real scientific or regulatory questions for FDA, the designation is just a press release. Identify three to five specific questions you would use sprint discussions to resolve before you apply.

4. Do not let the designation pull you off your EU strategy. A designation is US-only. If your commercial plan is EU-first, the designation adds work without accelerating your lead market. Sequence it after your EU launch, not instead of it.

5. Keep your evidence plan honest. Do not shrink your pivotal trial because you got a designation. The statutory standard has not changed. Shrinking the trial because you got a designation is one of the fastest ways to get a Not Substantially Equivalent letter or a PMA denial.

6. Build the designation request into your regulatory project plan. The application itself takes real work — typically 40 to 80 pages including a device description, evidence of eligibility, and justification. Budget accordingly and nominate a single owner.

7. Plan for the post-designation communications cadence. Once designated, FDA expects you to engage. If you disappear for a year, the designation loses its practical value. Build the FDA interaction plan before you apply.

Reality Check

  1. Does our device actually target a life-threatening or irreversibly debilitating condition, or are we stretching the definition?
  2. Can we name the single innovation criterion we will argue, and do we have evidence to back it?
  3. Do we have three to five specific scientific questions we would use sprint discussions to resolve?
  4. Have we budgeted 40 to 80 pages of focused regulatory writing for the designation request itself?
  5. Is our US launch genuinely a priority, or is this designation being pursued for press and investor signaling only?
  6. Does our evidence plan assume the same statutory standard of safety and effectiveness that a non-designated device would need to meet?
  7. Have we confirmed that the designation does not affect our MDR strategy, timeline, or Notified Body interactions?
  8. Do we have an owner inside the team for the ongoing FDA relationship that comes with a designation?

Frequently Asked Questions

Does Breakthrough Designation mean my device is FDA approved? No. It is a pre-market designation that gives you more interactive communication with FDA. The actual marketing submission (De Novo, 510(k), PMA, or HDE) still has to clear or be approved on its own merits.

Does it shrink my clinical trial? No. The statutory standard of safety and effectiveness is unchanged. A designation may help you agree with FDA on trial design faster, but it does not reduce the evidence you need.

Does EU MDR have a breakthrough pathway? No direct equivalent. The closest mechanisms are the MDCG expert panel consultations under MDR Article 106 for certain high-risk devices, structured dialogues with some Notified Bodies, and innovation support from programs like the EIC Accelerator. These are different mechanisms with different effects and are not a drop-in replacement for a Breakthrough Designation.

Can an EU-only startup apply? The designation is an FDA program and only makes sense if you are pursuing a US market submission. If you have no plans to market in the US, the designation does nothing for you.

Does Breakthrough Designation affect reimbursement? In the US it may support separate reimbursement pathways through CMS, but that is a separate process with its own rules. Do not assume a designation guarantees favorable reimbursement.

How long does the designation request take to decide? FDA targets a response within 60 calendar days of receipt of a complete designation request. Complex cases can take longer. Plan accordingly.

Sources

  1. Federal Food, Drug, and Cosmetic Act, Section 515B — Priority review for breakthrough devices.
  2. 21st Century Cures Act, Public Law 114-255, Section 3051.
  3. FDA guidance on the Breakthrough Devices Program (current version).
  4. Regulation (EU) 2017/745 on medical devices, consolidated text. Article 61 and Article 106 for EU clinical evaluation and expert panel context.